Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study

被引：0
|
作者：
Mustafayev, Khalis [1 ]
Guevara, Eduardo Yepez [1 ]
DiNardo, Courtney D. [2 ]
Jabbour, Elias [2 ]
Ghayas, Issa C. [2 ]
Ratan, Ravin [3 ]
Pemmaraju, Naveen [2 ]
Torres, Harrys A. [1 ,4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX USA
来源：
LEUKEMIA RESEARCH | 2024年 / 147卷
关键词：
Dasatinib; Imatinib; Ponatinib; Chronic myeloid leukemia; Viral hepatitis; HCV;
D O I：
10.1016/j.leukres.2024.107597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors
    Mauro, Michael
    Lang, Fabian
    Kim, Dong-Wook
    Heinrich, Michael
    Sasaki, Koji
    Lyssikatos, Joe
    Collins, Helen
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S345 - S345
  • [22] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Malik, Sara
    Hassan, Shahzeb
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
  • [23] Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients
    Kockerols, Camille
    Valk, Peter J. M.
    Janssen, Jeroen J. W. M.
    Hogenbirk, Pauline
    Cornelissen, Jan J.
    Saussele, Susanne
    Spiess, Birgit
    Perusini, Maria Agustina
    Kim, Dennis
    Westerweel, Peter E.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (05) : 606 - 613
  • [24] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [25] Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
    Abu Seman, Zahidah
    Ahid, Fadly
    Kamaluddin, Nor Rizan
    Sahid, Ermi Neiza Mohd
    Esa, Ezalia
    Said, Siti Shahrum Muhamed
    Azman, Norazlina
    Mat, Wan Khairull Dhalila Wan
    Abdullah, Julia
    Ali, Nurul Aqilah
    Khalid, Mohd Khairul Nizam Mohd
    Yusoff, Yuslina Mat
    BMC RESEARCH NOTES, 2024, 17 (01)
  • [26] A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
    Limsuwanachot, Nittaya
    Rerkamnuaychoke, Budsaba
    Niparuck, Pimjai
    Singdong, Roongrudee
    Kongruang, Adcharee
    Hirunpatrawong, Piyapha
    Siriyakorn, Thanaporn
    Yenchitsomanus, Pa-thai
    Siriboonpiputtana, Teerapong
    JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB, 2023, 28 : 122 - 132
  • [27] The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
    Clapper, Erin
    Di Trapani, Giovanna
    Tonissen, Kathryn F.
    HEMATO, 2021, 2 (02): : 237 - 254
  • [28] Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
    Erbilgin, Yucel
    Eskazan, Ahmet Emre
    Ng, Ozden Hatirnaz
    Salihoglu, Ayse
    Elverdi, Tugrul
    Firtina, Sinem
    Tasar, Orcun
    Mercan, Sevcan
    Sisko, Sinem
    Khodzhaev, Khusan
    Ongoren, Seniz
    Ar, Muhlis Cem
    Baslar, Zafer
    Soysal, Teoman
    Sayitoglu, Muge
    Ozbek, Ugur
    LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 200 - 207
  • [29] LncRNA CBR3-AS1 is associated with the BCR::ABL1 kinase independent mechanism of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia patients
    Lin, Wuqiang
    Chen, Xiuli
    Zheng, Heyong
    Cai, Zhenjie
    Xie, Linjun
    Zhang, Beibei
    Zheng, Rongrong
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07) : 3262 - 3272
  • [30] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
12345